Cougar Biotechnology Names Richard B. Phillips, Ph.D. Vice President of Regulatory Affairs and Quality Assurance

Los Angeles, CA, February 14, 2007  /PRNewswire-FirstCall/ -- Cougar Biotechnology, Inc. (OTC:CGRB) (BULLETIN BOARD: CGRB) , a biotechnology company focused on acquiring and developing oncology drug candidates, today announced the appointment of Richard B. Phillips, Ph.D., to the position of Vice President of Regulatory Affairs and Quality Assurance. Dr. Phillips will lead the Company's interaction and liaison with the U.S. Food and Drug Administration (FDA), as well as with the European and other regulatory agencies. He will be responsible for all regulatory communications, filings, and strategy as well as Cougar's compliance with Good Clinical, Good Laboratory and Good Manufacturing Practices.

Dr. Phillips brings to Cougar over 20 years of regulatory affairs and quality assurance experience in the pharmaceutical and biotechnology industries. From 2005 until joining Cougar, Dr. Phillips was employed by Amgen Inc., where he was the Director of Regulatory Affairs and Global Regulatory Leader for Vectibix(TM) (panitumumab), which received FDA approval last year for the treatment of metastatic colorectal cancer. Prior to Amgen, Dr. Phillips served as Vice President of Regulatory Affairs and Quality Assurance at Chugai Pharma USA from 2002 to 2004, where he was responsible for eight development programs in five therapeutic areas, including oncology. He has also held regulatory affairs management positions with Pfizer Inc. (Parke- Davis), Johnson & Johnson (Janssen, L.P.), Sandoz (Novartis AG) and Structural GenomiX.

Dr. Phillips earned a Ph.D. in chemistry from the University of California, Berkeley, and a B.A. in chemistry from the University of California, Irvine.

Dr. Arie S. Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology, said, "Richard brings to Cougar a rich background in regulatory affairs and quality assurance, which is becoming an increasingly important focus for the Company as Cougar's drugs progress through clinical development. We are pleased to have someone of Richard's caliber join the senior management of the Company."

Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "Defining the specific regulatory strategy for each of Cougar's drugs in development has clearly become a focal point for the Company, most notably as our lead compound CB7630, abiraterone acetate, progresses through clinical development. Richard's strong regulatory affairs background and outstanding leadership abilities will be a great asset to Cougar and we look forward to the contributions that he will make to the senior management of the Company."

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at http://www.cougarbiotechnology.com/.

This press release contains forward-looking statements that involve risks and uncertainties that could cause Cougar's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the development of CB7630 or Cougar's other product candidates will ever be successfully completed, or that Cougar will ever receive the regulatory approvals to necessary to commercialize CB7630 or Cougar's other product candidates. Other risks that may affect forward-looking information contained in this press release include the risk that the results of clinical trials may not support Cougar's claims, Cougar's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 7, 2006. Cougar assumes no obligation to update these statements, except as required by law.

  Contacts:
  Cougar Biotechnology, Inc. -- [phone]
  Alan H. Auerbach, Chief Executive Officer and President
  
  Mariann Ohanesian, Director of Investor Relations
  

  Noonan Russo
  David Schull, [phone]
  
  Andreas Marathovouniotis, [phone]
  

DATASOURCE: Cougar Biotechnology, Inc.



CONTACT:  Alan H. Auerbach, Chief Executive Officer and President,

, or Mariann Ohanesian, Director of Investor

Relations, , both of Cougar Biotechnology,

Inc., [phone]; David Schull, [phone],

, or Andreas Marathovouniotis, [phone],

, both of Noonan Russo for Cougar Biotechnology,

Inc. 



Web site:  http://www.cougarbiotechnology.com/ 

Copyright